68 results
Page 2 of 4
8-K
EX-10.1
uvbi23d
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
424B3
ocb4u2x
6 Jul 22
Prospectus supplement
2:43pm
8-K
EX-10.1
jvnw9gwir0wv7xxjwi93
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
8-K
EX-10.2
qfemyszmz7wrosh7zsl
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
gw3vrvrc eafv
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
zly65go
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-10.1
knwe3cbz5
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
ew6cx73m05h5iapds5
7 Apr 22
Prospectus supplement
4:46pm
S-3
58kao leub3lej63ai
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
11jam
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
DEF 14A
w0ynxy59hrdpjmiys
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
v5451
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
10-K
6r7we4td qdu2ztjarx
24 Sep 21
Annual report
7:31am